Oct4 Regulates the Transition of Cancer Stem-Like Cells to Tumor Endothelial-Like Cells in Human Liver Cancer

Hong-Lin Liu,Hong-ting Tang,Han-lin Yang,Ting-Ting Deng,Ya-Ping Xu,Shi-Qing Xu,Liang Peng,Zai Wang,Qing Fang,Xiao-Yan Kuang,Qin-Shan Li

DOI: https://doi.org/10.3389/fcell.2020.563316

IF: 5.5

2020-09-30

Frontiers in Cell and Developmental Biology

Abstract:Octamer-binding transcription factor 4 (Oct4) has been recently implicated as a proangiogenic regulator in several induced pluripotent stem cells (iPSCs), however, its role in cancer stem-like cells (CSCs) remain unclear. We report here that Oct4 participates in tumor vasculogenesis in liver CSCs (LCSCs). We identify that LCSCs possess the potential of endothelial <i>trans</i>-differentiation under endothelial induction, present endothelial specific markers and their functions <i>in vitro</i>, and participate in neovasculogenesis <i>in vivo</i>. The knockdown of the Oct4A by short hairpin RNA (shRNA) in LCSCs represses endothelial <i>trans</i>-differentiation potential, but induces endothelial lineage-restricted differentiation, the latter is positively regulated by Oct4B1. Furthermore, Oct4 regulates vasculogenesis in LCSCs may be via the AKT-NF-κB-p65 signaling pathway. This work reveals Oct4, which is a crucial regulator, plays a critical role in tumor endothelial-like cells transition of LCSCs through Oct4A and Oct4B1 by different ways. The simultaneous inhibition of both the isoforms of Oct4 is hence expected to help regress neovascularization derived from CSCs. Our findings may provide insights to the possible new mechanisms of tumor vasculogenesis for primary liver cancer.

cell biology,developmental biology

What problem does this paper attempt to address?

This paper aims to explore the role of Oct4 in the transition of liver cancer stem cells (LCSCs) to tumor endothelial-like cells and its molecular mechanisms. Specifically, researchers found that Oct4 is involved in the angiogenesis process of LCSCs and regulates this process in different ways through different isoforms (Oct4A and Oct4B1). Additionally, they discovered that inhibiting Oct4A suppresses the transdifferentiation potential of LCSCs into endothelial cells but induces their differentiation into the endothelial lineage, a process positively regulated by Oct4B1. The findings suggest that simultaneously inhibiting all isoforms of Oct4 may help reverse the neovascularization originating from cancer stem cells, providing a new perspective for liver cancer treatment.